http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019172622-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afcfc7af43784847a2171ad49795c3c3 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
| filingDate | 2018-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1450bc5476bd42274b7decb3c6bc50c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7e03666da7e222118a46ced9062494d |
| publicationDate | 2019-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2019172622-A |
| titleOfInvention | Non-alcoholic steatohepatitis therapeutic agent |
| abstract | In non-alcoholic steatohepatitis, exercise and diet therapy and pharmacotherapy are applied as necessary when inflammation is relatively mild. The purpose of this study was to develop a non-alcoholic steatohepatitis therapeutic agent by suppressing tissue fibrosis. The gene expression in a non-alcoholic steatohepatitis model and a simple fatty liver model was compared, and IL17, whose expression was improved in the non-alcoholic steatohepatitis model, was noted. It was confirmed that anti-IL17 antibody suppresses fibrosis of liver tissue in nonalcoholic steatohepatitis, and a nonalcoholic steatohepatitis therapeutic agent containing anti-IL17 antibody was completed. [Selection figure] None |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112646030-A |
| priorityDate | 2018-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 119.